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Given the oft scarcity of food, the ability to survive bouts of starvation is one key driving force of evolution. Mammals respond to fasting by activating an enormous cascade of interconnected processes that are precisely coordinated by an array of hormones. Two such coordinated processes during the early stages of fasting are appetite stimulation and hepatic glucose release into the circulation, which, together, ensure the drive to obtain food and to keep the brain nourished and alert while foraging.
Through the study of a rare genetic condition in humans, neonatal progeroid syndrome (NPS; also known as Marfan lipodystrophy syndrome, OMIM ID 616914), we recently discovered a ~30 kDa fasting-induced hormone, asprosin, that is highly expressed in adipose tissue and that, when secreted, stimulates hepatic glucose release 1 . Asprosin is the 140-residue, C-terminal product of the fibrillin 1 protein (encoded by FBN1). Consistent with the necessity for hepatic glucose release during fasting, the circulating concentration of asprosin rises with fasting and drops with refeeding in an acute manner, displaying circadian rhythmicity in coordination with the nutritional state. Here we demonstrate that peripherally (intravenously) administered asprosin crosses the blood-brain barrier (BBB) to activate the hypothalamic feeding circuitry, which leads to appetite stimulation and, over the long term, to the maintenance of adiposity. Our results demonstrate coordination between two critical pillars of the mammalian fasted state-appetite stimulation and hepatic glucose release-via the same fasting-induced hormone, asprosin, through spatiotemporally distinct mechanisms in the liver and the hypothalamus.
RESULTS

Individuals with neonatal progeroid syndrome display hypophagia
We previously elucidated the complex molecular genetics of NPS that led us to the protein hormone asprosin 1 . Individuals with NPS have heterozygous, truncating mutations in the FBN1 gene 1 and display a deficiency in circulating (plasma) asprosin 1 that is associated with extreme leanness (Fig. 1) 1, 2 , reduced subcutaneous adipose mass ( Fig. 1) 2 and maintenance of insulin sensitivity despite partial lipodystrophy 1, 2 . To better understand the energy balance equation in individuals with NPS within the context of the observed leanness, we measured food intake and energy expenditure using two independent methods each ( Table 1) . We found that the two individuals examined consumed fewer calories on a daily basis than their age-and sex-matched peers in the lab, as well as in the home setting ( Table 1) . Their hypophagia was matched by subnormal daily energy expenditure, as measured using indirect calorimetry (lab setting) or the doubly labeled water (DLW) method (home setting) ( Table 1) .
In addition to 24-h caloric intake and 24-h energy expenditure measurements, we determined additional parameters related to energy balance to obtain a comprehensive physiological view of the patients with NPS and to reinforce the conclusion that their energy balance equation was tilted in the favor of low caloric intake ( Supplementary  Tables 1 and 2 ). On the basis of these results we hypothesized that NPS-associated leanness could at least partially be explained by asprosin deficiency and that asprosin is necessary for normal levels of appetite in humans.
Modeling NPS in mice and determining their physiology
We recapitulated the genetic architecture of mutations associated with human NPS in mice using the CRISPR-Cas9 gene editing system. We introduced a small heterozygous deletion (10 bp) that encompassed the border between exon 65 and intron 65 in mouse Fbn1 (Fig. 2a) . This deletion led to the skipping of exon 65 and resulted in a frameshift that led to heterozygous ablation of the asprosin-coding region (Fig. 2a) , thus creating Fbn1 NPS/+ mice that harbor a molecular event identical to that documented in a known individual with NPS 3 . Similar to human NPS 1 , we found that there was less than 50% asprosin in these mice, as compared to asprosin concentrations in wild-type (WT) mice, despite the heterozygosity (Fig. 2b) , presumably due to a previously postulated dominant-negative mechanism of action of the mutant allele 1 . Similar to humans with NPS 2 , Fbn1 NPS/+ mice displayed extreme leanness as compared with their sex-matched WT littermates (Fig. 2c) , and this was confirmed using dual-energy x-ray absorptiometry (DEXA) scans to be due to reduction in both fat mass and lean mass with no statistically significant change in body length (Fig. 2d) . The reduction in lean mass is not unexpected given the underlying Marfan syndrome, which is associated with a reduction in muscle mass and is part of the NPS phenotype owing to a mutant fibrillin-1 protein 4 . Concentrations of the hormone leptin were significantly lower in Fbn1 NPS/+ mice that had been fed either normal chow or a high-fat diet (HFD) than in WT littermate control mice, consistent with their low fat mass ( Supplementary Fig. 1a,b) .
We placed Fbn1 NPS/+ mice and WT littermate controls on a HFD for 3 months and found a widening difference in body weight and fat mass between the two groups (Fig. 2e) . On normal chow, the body weight curves of Fbn1 NPS/+ mice were already markedly different from those of WT mice at weaning age (3 weeks old), culminating in a 10-g weight difference between the groups at 10 weeks of age (Fig. 2f) . We exposed mice to severe diabetogenic and obesogenic stress (HFD for 6 months; 60% calories from fat) and found that, as compared with WT mice, Fbn1 NPS/+ mice were completely protected from both obesity and diabetes ( Supplementary Fig. 1c-e) . Similar to that seen in the human disorder, within the context of thinness, Fbn1 NPS/+ mice displayed hypophagia (Fig. 2g) along with a likely compensatory reduction in energy expenditure (Fig. 2h) . Energy expenditure was also assessed using analysis of covariance (ANCOVA) (Fig. 2i) to avoid the confounding effects of preexisting low body weight and lean mass in Fbn1 NPS/+ mice, allowing for adjustment of the covariates 5 .
The reduction in energy expenditure displayed by Fbn1 NPS/+ mice normalized completely after the mice were fed a HFD ( Supplementary  Fig. 1f,g ), suggesting that the reduction in energy expenditure observed when the mice were fed normal chow in the setting of human and rodent NPS is a compensatory means to prevent a daily energy deficit, and that when daily energy deficit is not a concern, this physiological adaptation to compensate for it disappears. We then assessed the respiratory exchange ratio in Fbn1 NPS/+ and WT mice and found no significant difference in substrate preference (Supplementary Fig. 1h ). As compared with WT mice, basic vital signs such as heart rate, blood pressure and body temperature ( Supplementary Fig. 1i-k) , as well as the thyroid hormone axis, were unaffected in Fbn1 NPS/+ mice (Supplementary Fig. 1l ). Additionally, we observed no Membrane potential (mV) *** *** WT Figure 2 Introducing the NPS-associated mutation in mice results in hypophagia, reduced adiposity, and protection from diet-induced obesity. (a) Left, schematic depiction of the CRISPR-Cas9 strategy used to generate Fbn1 NPS/+ mice. A small (10 bp) deletion was introduced at the junction of exon 65 and intron 65 (top left) that resulted in loss of a splice site, skipping of exon 65 (middle left), and truncation of profibrillin (bottom left), which is identical to the molecular events in an individual with NPS 3 . Right, Fbn1 genomic sequence traces (top) and mRNA sequences (middle), and translated Fbn1 protein sequences (bottom), in ear snips from the WT and Fbn1 NPS/+ mice. (b) Endogenous asprosin in the plasma of WT (n = 6) and Fbn1 NPS/+ (n = 7) mice, as measured using sandwich ELISA. (c) Photograph of a representative set (n = 12 mice per group) of 5-month-old male WT mice and Fbn1 NPS/+ littermates that had been on a HFD for 3 months. (d,e) Body composition data using DEXA scans for WT and Fbn1 NPS/+ mice that were fed normal chow (WT, n = 8 mice; Fbn1 NPS/+ , n = 7 mice) (d) or a HFD (n = 8 mice per group) for 3 months. (f) Weight curves of WT and Fbn1 NPS/+ mice that were fed normal chow from 4 to 14 weeks of age (n = 6 mice per group; P = 0.008 by analysis of variance (ANOVA) when comparing genotypes). Throughout, data are presented as mean ± s.e.m. Box plots show whiskers at the minimum and maximum, the box around the 25th-75th percentile, a line at the median, and a dot at the mean where appropriate. *P < 0.05, **P < 0.01, and ***P < 0.001; by two-tailed t-test (b,d,e) or ANOVA (f-h,j).
off-target effects of the CRISPR-Cas9 strategy used for the generation of Fbn1 NPS/+ mice, at four distinct bioinformatically predicted susceptible loci (Supplementary Fig. 1m ).
Neurons that express agouti-related neuropeptide (AgRP + neurons) are a well-studied population of orexigenic neurons located in the arcuate nucleus of the hypothalamus (ARH) [6] [7] [8] . In conjunction with low appetite, we found that the activity of AgRP + neurons from Fbn1 NPS/+ mice was significantly lower than that of AgRP + neurons from WT littermates, as demonstrated by decreased firing frequency and resting membrane potential (Fig. 2j) . Notably, an overnight fast, which normally results in a marked increase in the activity of AgRP + neurons, had no effect in Fbn1 NPS/+ mice (Fig. 2j) , suggesting that a deficiency in asprosin renders these neurons unable to respond, even to other potentially compensatory factors. Consistent with this observation, we found that ghrelin, a well-known orexigenic hormone, and asprosin acted on a partially overlapping subset of AgRP + neurons (Supplementary Fig. 2a) . Additionally, ghrelin showed a decreased ability to activate AgRP + neurons from Fbn1 NPS/+ mice, as compared with those from WT mice (Supplementary Fig. 2b ).
Asprosin is sufficient to rescue key phenotypes of Fbn1 NPS/+ mice A single subcutaneous dose of recombinant asprosin (rAsprosin) was sufficient to completely rescue the hypophagia phenotype of Fbn1 NPS/+ mice, demonstrating that NPS-associated hypophagia is due to a deficiency of plasma asprosin and not due to some indirect effect of mutated Fbn1 (Fig. 3a) . In a complementary experimental approach, we found that a single intracerebroventricular (ICV) injection of rAsprosin in Fbn1 NPS/+ mice largely restored the firing rate of AgRP + neurons and completely restored their resting membrane potential to the levels seen in the AgRP + neurons of recombinant GFP (rGFP)-injected WT mice (Fig. 3b) .
As a third level of evidence, the mouse-NPS-associated decrease in AgRP + neuron membrane potential and firing frequency were completely rescued by simple incubation of intact hypothalamic slices with rAsprosin but not with rGFP (Fig. 3c) . These results represent the highest level of evidence that NPS-associated hypophagia and depressed AgRP + neuron activity are due to a deficiency in asprosin and that normal asprosin concentrations in the blood are necessary to maintain appropriate appetite and AgRP + neuron function.
Asprosin crosses the blood-brain barrier and stimulates appetite in rodents We assessed asprosin concentrations in rat cerebrospinal fluid (CSF) with an asprosin-specific 1 sandwich enzyme-linked immunosorbent assay (ELISA) and found it to be present in CSF at concentrations fourfold to fivefold below those in the plasma (Fig. 4a versus plasma levels reported in Romere et al. 1 ). Similar to plasma asprosin, asprosin levels in the CSF were increased by overnight fasting (Fig. 4a) . To assess whether plasma asprosin could cross the BBB and enter the CSF, we injected rats intravenously with rAsprosin that had an N-terminal histidine (His)-tag and tested for the presence of the His-tag in the CSF by ELISA (Fig. 4b) . One hour after the intravenous injection we detected a strong signal for the His-tag in the CSF, which was matched by a sixfold increase in CSF asprosin, suggesting that plasma asprosin was able to enter into the CSF (Fig. 4b) .
To ascertain whether asprosin stimulates appetite, we administered a single dose of bacterially expressed or mammalian-expressed rAsprosin or rGFP subcutaneously to WT mice. Asprosin-injected neurons; firing frequency: WT + rGFP, n = 12 neurons; Fbn1 NPS/+ + rGFP, n = 11 neurons; Fbn1 NPS/+ + rAsprosin, n = 13 neurons). Throughout, data are presented as mean ± s.e.m. Box plots show whiskers at the minimum and maximum, the box around the 25th-75th percentile, a line at the median, and a dot at the mean where appropriate. *P < 0.05, **P < 0.01, and ***P < 0.001; by one-way ANOVA.
mice displayed greater food intake than GFP-injected mice over the next 24 h irrespective of which rAsprosin preparation was used (Fig. 4c,d ). Of note, mammalian-generated asprosin was about twice the molecular weight of bacterially generated asprosin, and, as predicted previously 1 , this difference was largely due to glycosylation of the mammalian-generated protein ( Supplementary Fig. 3a,b) . The plasma half-life of the mammalian-generated asprosin was ~145 min (Supplementary Fig. 3c ) (as compared to ~20 min for the bacterially generated version 1 ), with a 60-µg subcutaneous dose producing a peak plasma level of 40 nM (Supplementary Fig. 3d ). Notably, there was a latent phase of a few hours after asprosin injection before the orexigenic effect was observed (Fig. 4c,d) , which differentiates the effects of asprosin from those of more acute-acting orexigenic agents such as ghrelin 9 . Consistent with the effect observed after subcutaneous injection of asprosin, we noted an orexigenic effect of asprosin after directly introducing it into the CSF via an ICV injection (Fig. 4e) . To understand chronic responses, we treated WT mice with daily subcutaneous doses of rAsprosin for 10 d. In addition to the expected hyperphagia ( Fig. 4f) , we found no statistically significant change in energy expenditure, fecal triglyceride content, or body weight ( Fig. 4g and Supplementary Fig. 3e,f) . We did observe a slight decrease in lean mass (likely due to the stress of daily injections) (Supplementary Fig. 3g ) and a significant increase in adiposity ( Fig. 4h) , which demonstrated a tilting of the energy balance equation in favor of increased energy intake. A second 10-d gain-offunction strategy using adenovirus-mediated hepatic human FBN1 overexpression that resulted in an approximately twofold increase in plasma asprosin 1 (Supplementary Fig. 3h ) showed a similar hyperphagic response (Fig. 4i) and body weight increase ( Supplementary  Fig. 3i ). There was no statistically significant change in energy expenditure or lean mass ( Fig. 4j and Supplementary Fig. 3j ). There was an increase in adiposity when the mice were fed normal chow (Fig. 4k) , and this effect was potentiated after subjecting the mice to a HFD (Fig. 4l) . Figure 4 Asprosin crosses the blood-brain barrier and stimulates appetite. (a) Quantification of endogenous asprosin, using a sandwich ELISA, in the CSF of rats that were provided normal chow ad libitum or fasted overnight (n = 7 rats per group). (b) Quantification of the N-terminal His-tag on bacterially expressed asprosin (left) and of total asprosin (recombinant + endogenous; right), using a sandwich ELISA, in the CSF of fasted rats after intravenous injection of bacterially expressed, His-tagged asprosin (30 µg protein/mouse; n = 4 rats per group). (c) Cumulative food intake in a 24-h period after a single subcutaneous injection of rGFP or bacterially expressed rAsprosin (30 µg protein) in mice, using CLAMS (n = 5 mice per group; P = 0.06 when comparing treatments). (d) Food intake in a 24-h period after a single subcutaneous injection of rGFP or mammalian-expressed rAsprosin (60 µg protein) in mice, using CLAMS (n = 6 mice per group; P = 0.0003 when comparing treatments). (e) Cumulative food intake during the dark phase (12 h) of circadian-entrained mice after ICV injection of rGFP or bacterially expressed rAsprosin (10 ng protein/mouse) (n = 8 mice per group). (f) Cumulative food intake over a 24-h period in mice that were exposed to 10 d of a single daily injection of rGFP or bacterially expressed rAsprosin (30 µg protein per mouse per day), using CLAMS (n = 5 mice per group). (g) Energy expenditure over a 24-h period in the mice from f, using CLAMS (P = 0.15). (h) Fat mass, as assessed by magnetic resonance imaging (MRI), in the mice from f before and after 10 d of a single daily injection of rGFP or bacterially expressed rAsprosin. (i) Cumulative food intake over a 24-h period in mice 10 d after adenoviral overexpression of GFP or FBN1, using CLAMS (n = 5 mice per group). (j) Energy expenditure over a 24-h period in the mice from i, using CLAMS (P = 0.46). (k) Fat mass in the mice from i, as assessed by MRI, before and 10 d after injection with an adenovirus overexpressing GFP or FBN1 (n = 5 mice per group; P = 0.06 between 0 and 10 d for the FBN1 group). (l) Fat mass in mice, as assessed by MRI, 1 and 3 weeks after injection with the GFP-or FBN1-overexpressing adenovirus (n = 5 mice per group). Throughout, data are presented as mean ± s.e.m. Box plots show whiskers at the minimum and maximum, the box around the 25th-75th percentile, a line at median, and a dot at the mean where appropriate. *P < 0.05 and **P < 0.01; by two-tailed t-test (a,b,e,f,i) or two-way ANOVA (c,d,g,h,j-l).
AgRP + neurons are essential for asprosin-mediated appetite stimulation We found that exposure to rAsprosin acutely induced activation of AgRP + neurons via an increase in firing frequency and an increase in resting membrane potential, whereas, expectedly, exposure to rGFP had no effect on these neurons (Fig. 5a) . We consistently observed that only ~50% of the AgRP + neurons were asprosin responsive, which suggested that only a subset of the cells contained the components necessary for transducing the asprosin-dependent signal (Fig. 5b) . In addition, we found that treatment with asprosin increased the amplitude but not the frequency of the miniature excitatory postsynaptic current (mEPSC) of AgRP + neurons (Fig. 5c,d ). This pattern suggests that exposure to asprosin increases the responsiveness of AgRP + neurons to excitatory inputs, probably via cell-autonomous mechanisms rather than by regulation of the presynaptic inputs per se. We confirmed this by pharmacologically inhibiting synaptic inputs to the AgRP + neurons and finding no decrease in asprosin-mediated activation (Fig. 5e-g ).
To ascertain whether AgRP + neurons were necessary for asprosinmediated appetite stimulation, we injected asprosin in WT mice and in mice in which AgRP + neurons had been ablated 8 . Ablation of AgRP + neurons completely eliminated asprosin's orexigenic drive in mice that were fed a normal chow diet (Fig. 5h) , demonstrating the in vivo requirement of AgRP + neurons for asprosin-mediated appetite stimulation. Of note, when exposed to a HFD, mice in which the AgRP + neurons had been ablated were still able to respond to asprosin (Supplementary Fig. 4a ), suggesting that a highly palatable diet was able to engage neuronal populations that were different from those involved in normal hunger signals 10 .
Asprosin activates AgRP + neurons via a G s -cAMP-protein kinase A axis We assessed the dose dependency of asprosin action in AgRP + neurons by exposing intact mouse hypothalamic slices to increasing doses of either bacterially expressed or mammalian-generated rAsprosin. We found a dose-dependent activation of AgRP + neurons at the levels of firing frequency and resting membrane potential for both preparations of asprosin (Supplementary Fig. 4b ). The half-maximal effective concentration (EC 50 ) values for both sources of asprosin were found to be in the nanomolar to subnanomolar range, demonstrating high sensitivity of action, well within the range at which endogenous asprosin is present in the CSF (Supplementary Fig. 4b) .
Asprosin-mediated activation of AgRP + neurons, at the level of both firing frequency and resting membrane potential, could be completely prevented by pretreating the cells with suramin (an inhibitor of heterotrimeric G proteins), NF449 (an inhibitor of the Gα s subunit of heterotrimeric G proteins), NKY80 (an inhibitor of adenylate cyclase), and PKI (an inhibitor of protein kinase A (PKA)) (Supplementary Fig. 4c) . Conversely, pre-treatment of the cells with PTX (an inhibitor of the Gα i subunit of heterotrimeric G proteins) or with [d-Lys 3 ]-GHRP-6 (an inhibitor of the ghrelin receptor) had no effect on asprosin's ability to activate AgRP + neurons (Supplementary Fig. 4c ). These results suggest that signaling via G proteins (specifically Gα s ), adenylate cyclase, cAMP, and PKA is necessary for asprosin-mediated activation of AgRP + neurons, whereas Gα i and the ghrelin receptor are dispensable. The same pattern was observed when we evaluated the proportion of AgRP + neurons that were activated by asprosin (Supplementary Fig. 4d ).
Asprosin inhibits anorexigenic POMC + neurons POMC + neurons are an anorexigenic population of neurons within the ARH that function coordinately with AgRP + neurons. We found that asprosin acutely inhibited ~85% of the POMC + neurons by reducing their resting membrane potential and firing frequency ( Supplementary Fig. 5a,b) . In addition, treatment with asprosin increased the frequency but not the amplitude of the miniature inhibitory postsynaptic current (mIPSC) in POMC + neurons (Supplementary Fig. 5c,d) . In contrast to the demonstrated direct action on AgRP + neurons, asprosin's ability to hyperpolarize POMC + neurons was found to be dependent on intact GABAergic input, suggesting an indirect effect of asprosin on POMC + neurons via surrounding GABAergic neurons (Supplementary Fig. 5e-g ). Blockade of glutamatergic inputs, however, did not affect asprosin-mediated POMC + neuron hyperpolarization (Supplementary Fig. 5f ). Because AgRP + neurons are a GABAergic neuronal population that project to POMC + neurons 11, 12 , we tested the effects of AgRP + neuron ablation on asprosin-mediated POMC + neuron hyperpolarization and found that it completely prevented asprosin-mediated hyperpolarization of POMC + neurons (Supplementary Fig. 5h ). This suggests that AgRP + neurons are at least one population of upstream GABAergic neurons that transduce asprosin's signal to POMC + neurons.
We expanded our studies to explore the effects of asprosin on other neural populations that are relevant for the regulation of feeding and/or energy expenditure. These included 5-hydroxytryptamine (5-HT)-positive neurons in the dorsal raphe nuclei (DRN), steroidogenic factor 1 (SF1)-positive neurons in the ventromedial hypothalamic nucleus (VMH), neurons in the paraventricular nucleus of the hypothalamus (PVH) and dopamine (DA + ) neurons in the ventral tegmental area (VTA). As presented in Supplementary Figure 6a : asprosin had no effect on any of the VMH SF1 + neurons and VTA DA + neurons that we recorded; asprosin only depolarized 7% of DRN 5-HT + neurons but left the remaining 93% unregulated; and asprosin depolarized 13% and hyperpolarized 4% of PVH neurons but left the rest (83%) unregulated. Thus, none of these four neural populations responded to asprosin in a manner that was comparable to that observed with AgRP + neurons.
In contrast, we found that PVH neurons from Fbn1 NPS/+ mice showed a significantly increased firing rate and resting membrane potential, as compared to that in PVH neurons from WT mice (Supplementary Fig. 6b) . Notably, ICV-injected asprosin in Fbn1 NPS/+ mice restored PVH neuron firing activities to the levels observed in WT mice (Supplementary Fig. 6b) . Because a direct application of asprosin did not alter the firing activities of the majority of PVH neurons in WT mice (as demonstrated in Supplementary  Fig. 6a) , the altered firing activities observed in PVH neurons from Fbn1 NPS/+ mice before and after treatment with asprosin probably reflect indirect effects that are secondary to changes in the firing of AgRP + neurons. Because PVH neuron activity can reflect melanocortin tone 13 , we tested the effect of inhibiting asprosin by using immunological neutralization with an asprosin-specific monoclonal antibody in the context of chronic melanocortin antagonism (Agouti yellow mice 14 versus WT mice). Similar to our previous observations with WT mice (Fig. 6b) , we found that treatment with the asprosin-specific antibody, versus that with a nonspecific, isotype-matched antibody, significantly reduced food intake in WT mice, despite the mice being of a different genetic background (KK strain) as compared with all of our previous studies on C57Bl/6 mice ( Supplementary Fig. 6c ). In contrast, asprosin neutralization had 30 µM CNQX (an NMDA receptor antagonist), 50 µM bicuculline (a GABA receptor antagonist), and 1 µM TTX) (bottom) (e) and amplitude changes of resting membrane potential in AgRP + neurons after treatment with rGFP (n = 8 neurons), with 1 nM (n = 12 neurons) or 34 nM (n = 44 neurons) bacterially expressed rAsprosin, or with 34 nM bacterially expressed rAsprosin in the presence of either TTX (n = 11 neurons) or the inhibitor cocktail (n = 13 neurons) (f). (g) Response ratio of AgRP + neurons after treatment with bacterially expressed rAsprosin in the presence of either TTX (n = 11 neurons) or the inhibitor cocktail (n = 13 neurons). (h) Cumulative food intake (normal chow) for WT mice and mice in which AgRP + neurons had been ablated in response to a single dose of rGFP or bacterially expressed rAsprosin (30 µg protein/mouse; n = 4 mice per group). Throughout, data are presented as mean ± s.e.m. Box plots show whiskers at the minimum and maximum, the box around the 25th-75th percentile, a line at the median, and a dot at the mean where appropriate. *P < 0.05 by two-tailed t-test (e), one-way ANOVA (f), or two-way ANOVA (h).
no effect whatsoever on food intake in age-and sex-matched Agouti yellow mice (Supplementary Fig. 6c ). This result is consistent with the observed stimulatory effects of asprosin on AgRP + neurons and indicates that asprosin-mediated appetite stimulation requires an intact melanocortin pathway.
Treatment with an asprosin-specific antibody reduces food intake and body weight in obese mice Immunological neutralization of asprosin using a monoclonal antibody (mAb) resulted in reductions in firing frequency and resting membrane potential in AgRP + neurons in mice that were fed normal chow (Fig. 6a) . This was also observed in vivo using Fos protein expression as a marker of AgRP + neuron activity (Supplementary Fig. 7a,b) . This was accompanied by a reduction in daily food intake without an associated change in energy expenditure (Fig. 6b,c) . We previously validated this antibody (Supplementary Fig. 8a ) for asprosin specificity 1 , and we performed detailed epitope mapping for it ( Supplementary  Fig. 8b) . We tested the neutralization activity of this antibody in vitro, which allowed us to calculate its IC 50 value ( Supplementary  Fig. 8c) , and extended that observation to a calculation of the likely minimum efficacious dose in mice with diabetes ( Supplementary  Fig. 8d) . As a proof of concept of its function in vivo, we found that there was a complete lack of neutralization activity in mice that had been treated with streptozotocin ( Supplementary Fig. 8e) , which results in a near absence of circulating asprosin 1 . Notably, we found that treatment with the asprosin-specific antibody, as compared to that with an isotype-matched IgG control antibody, completely neutralized asprosin's ability to activate AgRP + neurons and inhibit POMC + neurons, (Supplementary Fig. 9a-j) , validating the effect of both rAsprosin and the asprosin-specific monoclonal antibody.
We previously demonstrated that human and mouse (as assessed by HFD-based experiments or by assessing mice with) a mutation in the leptin gene (Lep ob/ob ) obesity is associated with a pathological increase (e) Energy expenditure over a 24-h period in the mice from d, using CLAMS (P = 0.22 when comparing treatments). (f) Weight change over time in 8-week-old male Lepr db/db mice that were treated with one daily injection of an IgG control antibody or an asprosin-specific mAb (250 µg/mouse) (n = 6 mice per group; P = 0.007 when comparing treatments). Original mean weights per group before treatment: 43.8 g for the IgG group and 46.9 g for the anti-asprosin group. (g) Cumulative food intake over a 24-h period, using CLAMS, in 20-week-old male WT mice that were fed a HFD for 3 months and that were administered a daily dose of an IgG control antibody or an asprosin-specific mAb (250 µg/mouse) for 5 d (n = 5 mice per group). (h) Energy expenditure over a 24-h period in the mice from g, using CLAMS (P = 0.67 when comparing treatments). (i) Weight change over time in 20-week-old male WT mice that were fed a HFD for 3 months and that were administered a daily dose of an IgG control antibody or an asprosin-specific mAb (250 µg/mouse) for 5 d (n = 6 mice per group; P = 0.05 when comparing treatments). Original mean weights per group before treatment: 50.1 g for the IgG group and 50.3 g for the anti-asprosin group. Throughout, data are presented as mean ± s.e.m. Box plots show whiskers at the minimum and maximum, the box around the 25th-75th percentile, a line at the median, and a dot at the mean where appropriate. *P < 0.05 and **P < 0.01; by two-tailed t-test (a,d,g) or two-way ANOVA (b,c,e,f,h,i).
in plasma asprosin 1 . We extended those results to another model of obesity in mice, those with a mutation in the gene encoding the leptin receptor (Lepr db/db ) (Supplementary Fig. 9k ). Similar to previously demonstrated improvements in the glycemic profile of insulin-resistant mice 1 , we found that immunologic neutralization of asprosin reduced daily food intake without affecting energy expenditure in a statistically significant manner in the Lepr db/db mice (Fig. 6d,e) . Daily intraperitoneal dosing over 5 d showed an improvement in body weight in addition to the reduced food intake (Fig. 6f) . Virtually identical results were obtained using WT mice that were on a HFD (Fig. 6g-i) . These results suggest that chronic pharmacological inhibition of asprosin function, such as with a mAb, produces appetite and body weight reductions, as are predicted from genetic studies of asprosin depletion in humans and mice.
DISCUSSION
Whether circulating concentrations of asprosin are experimentally decreased (genetic depletion in individuals with NPS, genetic depletion in Fbn1 NPS/+ mice, or acute removal via immunologic neutralization in mice) or increased (adenovirus-mediated overexpression or recombinant protein injection), the result is a corresponding consistent change in appetite and adiposity. Asprosin-mediated AgRP + neuron activation seems to be central to these effects, as ablation of AgRP + neurons renders asprosin's orexigenic drive ineffective in mice fed a normal chow diet. However, it remains possible that asprosin could also exert its appetite-stimulating action via other populations of orexigenic and anorexigenic neurons in addition to the AgRP + neurons, as suggested by the ability of AgRP + -neuron-ablated mice to respond to asprosin after being subjected to a HFD. Similar to what has been observed in the liver 1 , the Gα s -cAMP-PKA axis is necessary for asprosin-mediated activation of AgRP + neurons. This is consistent with the known orexigenic effect of Gα s and cAMP signaling in AgRP + neurons 15 , demonstrating a previously unknown circulating factor whose orexigenic activity is centered on this pathway. Furthermore, asprosin inhibited anorexigenic POMC + neurons, which was dependent on intact GABAergic synaptic input. AgRP + neurons are GABAergic neurons that project to POMC + neurons, and their functional relevance was confirmed by the observation that their ablation largely prevented asprosin-mediated inhibition of POMC + neuron activity.
Individuals with NPS have a marked deficit in plasma asprosin along with phenotypic parameters of hypophagia, reduced subcutaneous adipose mass and very low body mass indices. The presence of a heterozygous Fbn1 NPS mutation in mice resulted in a virtual phenocopy of human NPS, with hypophagia, and low adipose mass and body weight. The mice also had reduced levels of AgRP + neuron activity. Replenishment of plasma asprosin in vivo, via a single subcutaneous injection, completely rescued hypophagia in Fbn1 NPS/+ mice, demonstrating the dependence of NPS-associated hypophagia on a deficiency in plasma asprosin. Notably, the addition of asprosin ex vivo to hypothalamic slices or in vivo using an ICV injection largely corrected the depressed firing rate and resting membrane potential of AgRP + neurons from Fbn1 NPS/+ mice, demonstrating the dependence of AgRP + neurons on asprosin for normal functioning.
Given that asprosin is a circulating hormone, immunologic neutralization using monoclonal antibodies is an attractive pharmacological loss-of-function strategy for potential therapeutic applications. We previously demonstrated the efficacy of this strategy against the glucogenic effects of asprosin in insulin-resistant mice by showing that treatment of HFD-fed and Lep ob/ob mice with an asprosin-specific mAb acutely lowers insulin concentrations 1 . Here we found that immunological neutralization of asprosin reduced baseline AgRP + neuron activity and resulted in a reduction in daily food intake. We extended those findings to obesity by demonstrating that chronic immunologic neutralization of asprosin in two independent mouse models of obesity (HFD-induced obesity and Lepr db/db mutation) resulted in a reduction in daily food intake along with a reduction in body weight. Of note, the absence of leptin signaling in the setting of the Lepr db/db mutation did not affect the result, suggesting distinct mechanisms of action for asprosin and leptin in AgRP + and POMC + neurons. Besides a compensatory decrease in energy expenditure in individuals with NPS and Fbn1 NPS/+ mice, no statistically significant effects on energy expenditure were observed in any of the experiments, suggesting that the effect of asprosin on the energy balance equation is predominantly on stimulation of appetite. Notably, AgRP + neurons are known to suppress energy expenditure, in addition to their appetite-stimulating function 7 . However, it is possible that the subset of AgRP + neurons activated by asprosin has a greater effect on appetite than on energy expenditure, as compared with the asprosinunresponsive subset.
FBN1 mRNA is present at much lower levels in the brain relative to other tissues 1 , and because we observed the migration of plasma asprosin through the BBB, it is likely that peripherally generated asprosin serves as a central appetite-modulating signal, similar to leptin. Organ-specific ablation of asprosin, particularly in adipose tissue, should help address this and other important questions. Another key question is how asprosin signaling fits in the balance exerted by existing orexigenic and anorexigenic hormones such as ghrelin, leptin, and insulin. We demonstrated that asprosin and ghrelin activate a partially overlapping subset of AgRP + neurons, an asprosin deficiency renders AgRP + neurons less responsive to ghrelin-mediated activation, the ghrelin receptor is dispensable for asprosin-mediated AgRP + neuron activation, and the leptin receptor (Lepr db/db mice) is dispensable for asprosin loss-of-function-induced reduction in food intake and body weight, and we previously demonstrated cross-talk with insulin's gluco-modulatory actions at the liver 1 . Additionally, the cell surface receptor for asprosin remains unidentified and is a focus of active work in our laboratory.
Thus, the emerging picture of asprosin is as a glucogenic and orexigenic hormone that originates in adipose tissue and is exquisitely sensitive to the whole-body energetic status by rising with fasting and abating with feeding. It performs two critical fasting-related functions (hepatic glucose production and appetite stimulation) using the same cAMP second messenger system, although using distinct spatiotemporal mechanisms at two distinct organs. It is possible that central (neuronal) asprosin action could influence its peripheral (hepatic) actions or vice versa, but this remains to be explored experimentally. Nevertheless, pathologic elevation of asprosin in human insulin resistance and obesity, and the observed efficacy of immunologic neutralization of asprosin against insulin resistance 1 and obesity in mice (this study), suggest that pharmacological disruption of asprosin function could serve as a potentially unique therapeutic avenue against such diseases.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. 
ONLINE METHODS
Study subjects and ethics statement. Informed consent and permission to use photographs and biological materials for research was obtained before participation from all of the subjects under Institutional Review Board (IRB)-approved protocols at Baylor College of Medicine. Study subjects were assessed, and genomic DNA was analyzed by either whole-exome or Sanger sequencing, as reported previously 1 .
Doubly labeled water (DLW) method. Total energy expenditure (TEE) was measured over a 10-d period using the DLW method [17] [18] [19] . After collection of the baseline urine samples, each participant orally received 0.086 g per kg body weight (g/kg) of 2 H 2 O at 99.9 atom % 2 H and 1.38 g/kg H 2 18 O at 10 atom % 18 O (Isotec, Miamisburg, OH). Seven urine samples (1 ml each) were collected at home on days 1-10 after receiving the 2 H 2 O dose. The urine samples were stored frozen before analysis by gas isotope-ratio mass spectrometry. For stable-hydrogen isotope ratio measurements, 10 µl of urine without further treatment were reduced to hydrogen gas with 200 mg zinc reagent (Biogeochemical Laboratory, Indiana University, Bloomington, IN) at 500 °C for 30 min. The 2 H/ 1 H isotope ratios of the hydrogen gas were measured with a Finnigan Delta-E gas isotoperatio mass spectrometer (Finnigan MAT, San Jose, CA). For stable-oxygen isotope ratio measurements, 100 µl of urine was allowed to equilibrate with 300 mbar of CO 2 of known 18 O content at 25 °C for 10 h using a VG ISOPREP-18 water-CO 2 equilibration system (VG Isogas, Limited, Cheshire, UK). At the end of the equilibration, the 18 O/ 16 O isotope ratios of the CO 2 were measured with a VG SIRA-12 gas isotope-ratio mass spectrometer (VG Isogas, Limited, Cheshire, UK). (34 m 3 ) calorimeter. During the 24-h period of calorimetry, the subjects adhered to a schedule of physical activity (treadmill walking), feeding, and sleeping. Heart rate and physical activity were recorded using Actiheart (CamNtech, Cambridge, UK). TEE, nonprotein energy expenditure (NPEE), respiratory quotient (RQ), and net substrate utilization were calculated from VO 2 , VCO 2 , and urinary nitrogen excretion. Basal metabolic rate (BMR) was measured in the morning 30 minutes after awakening after a 12-h fast. The subjects had not had access to food after 7 PM the previous evening. Sleeping EE was measured for the entire night sleep period, which was confirmed by monitoring motion sensors and the heart rate. Activity energy expenditure (AEE) was computed as AEE = TEE − BMR − (0.1 × TEE) assuming diet-induced thermogenesis to be 10% of TEE. The physical activity level (PAL) was defined as the ratio TEE/BMR. The energy cost of walking for one individual was measured while walking at a speed of 2.5 m.p.h. and 3.5 m.p.h. for 15 min on a treadmill (Vision Fitness T9600).
Human room respiration calorimetry (indirect calorimetry). Energy expenditure was measured for 24 h in a large
Dietary recall.
A multiple-pass 24-h dietary recall was recorded in person by a registered dietitian using Nutrition Data Systems for Research (NDSR) (database version 2005, Nutrition Coordinating Center, University of Minnesota, Minneapolis) 20 , food models, and household measures and dishware. The 24-h recall was obtained without prior notice. The multiple-pass 24-h recall method uses three distinct passes to garner information about a subject's food intake during the preceding 24 h. Water consumption and vitamin mineral supplements were not included in the dietary assessment. The dietary recall was analyzed by NDSR, nutrient intakes were computed, and these measures were used to evaluate diet quantity and quality against the standards set by the Dietary Reference Intakes (DRI).
Mice. All mouse experiments were performed under animal protocols approved by the Baylor College of Medicine Institutional Animal Care and Use Committee and adhered to the guidelines of the Guide for the Care and Use of Laboratory Animals 21 . We used 6-to 12-week-old male WT mice for in vivo studies. These are abbreviated as 'WT' in the text. Lepr db/db obese mice, and A y /a and a/a mice, to assess involvement of melanocortin signaling, were purchased from the Jackson Laboratories. AgRP + -neuron-ablated mice were generated by injecting AgRP-DTR mice, which express diphtheria toxin receptor selectively in AgRP + neurons 22 with diphtheria toxin (DT; 50 ng/g, subcutaneous; Sigma Aldrich D0564) during the first week after birth 8, 10 ; AgRP-DTR mice injected with saline served as control mice. For experiments with AgRP + -neuron-ablated mice on a HFD, AgRP-DTR mice and WT mice were injected with DT. Fbn1 NPS/+ mice were generated at the Baylor College of Medicine Mouse Embryonic Stem Cell Core using a Crispr-Cas9 approach, and a colony was maintained in-house. Crispr-Cas9 mutagenesis was confirmed by running PCR using primers flanking the mutation site, followed by sequencing of the PCR product. In silico prediction of off-target effects was performed using the Cas-OFFinder 23 , and no off-target effects within known genes were found. Mice were backcrossed to WT C57Bl/6 mice for six generations to minimize possible off-target mutations. Assessment of off-target mutations in four independent non-gene-coding regions (using three mismatches as a reference) was carried out, and no off-target mutagenesis was identified (Supplementary Fig. 1m ). 6-to 12-week-old male WT and Fbn1 NPS/+ littermates were used for all experiments. Two to five mice were housed per cage in a 12-h light:12-h dark cycle with ad libitum access to food and water ('normal chow'; LabDiet 5V5R, which contains 63.3% calories from carbohydrates, 22% calories from protein, and 14.7% calories from fat). For diet-induced obesity studies, mice were placed on an adjusted-calories diet that provided 60% of calories from fat (Envigo Teklad TD.06414) for 12-16 weeks, unless otherwise indicated. Mice were exposed to adenoviral transduction (10 11 virus particles per mouse) via tail vein injections as described previously 1 . To obtain CSF for asprosin analysis, we contracted BioreclamationIVT to inject 8-to 12-week-old male rats intravenously with His-tagged rAsprosin, and euthanize them and obtain the CSF 1 h after injection. Flash-frozen CSF was shipped to us for further analysis. Glucose tolerance tests (GTTs) were performed using standard procedures. A 1.5 mg/g glucose bolus was used. Mice that had streptozotocin-induced diabetes were generated as reported previously 1 .
Labeling of neuronal populations. Whole-cell patch clamp recordings were performed on identified AgRP + neurons or POMC + neurons in the brain slices containing the ARH. In particular, to identify AgRP + neurons, we crossed the Rosa26-tdTOMATO mice with Agrp-Cre mice 12 to generate Agrp-Cre × Rosa26-tdTOMATO mice, which express TOMATO selectively in AgRP + NPY + neurons. In some studies, we crossed NPY-GFP mice 24 with Fbn1 NPS/+ mice to generate NPY-GFP mice that had or did not have the NPS-associated mutation, and GFP-labeled neurons in the ARH were recorded. To record POMC + neurons, we crossed Rosa26-tdTOMATO mice with Pomc-Cre ERT2 mice 25 to generate Pomc-Cre ERT2 × Rosa26-tdTOMATO mice, which express TOMATO selectively in mature POMC + neurons after tamoxifen treatment (0.2 mg/g, by intraperitoneal injection at 6 weeks of age). For some of the studies, we crossed the Agrp DTR/+ allele onto Pomc-GFP mice, and these mice received DT or saline injections (as described above) to generate mice in which AgRP + neurons were not or were ablated. Similarly, we used Tph2-Cre ERT2 × Rosa26-tdTOMATO mice 26 and Slc6a3-Cre ERT2 × Rosa26-tdTOMATO mice 27 to label 5-HT + neurons and DA + neurons, respectively, after tamoxifen treatment. We used Sf1-Cre × Rosa26-tdTOMATO mice 28 to label steroidogenic factor 1 (SF1 + ) neurons in the VMH.
Electrophysiology. Mice (6-12 weeks old) were deeply anesthetized with isoflurane and were transcardially perfused with a modified ice-cold sucrosebased cutting solution (pH 7.3; containing 10 mM NaCl, 25 mM NaHCO 3 , 195 mM sucrose, 5 mM glucose, 2.5 mM KCl, 1.25 mM NaH 2 PO 4 , 2 mM sodium pyruvate, 0.5 mM CaCl 2 , and 7 mM MgCl 2 , bubbled continuously with 95% O 2 and 5% CO 2 ) 29 . The mice were then decapitated, and the entire brain was removed and immediately submerged in the cutting solution. Slices (250 µm) were cut with a Microm HM 650V vibratome (Thermo Scientific). Three brain slices containing the ARH were obtained for each mouse (bregma −2.06 mm to −1.46 mm; interaural 1.74 mm to 2.34 mm), and recordings were made at levels throughout this brain region. The slices were recovered for 1 h at 34 °C and then maintained at room temperature in artificial cerebrospinal fluid (aCSF, pH 7.3; containing 126 mM NaCl, 2.5 mM KCl, 2.4 mM CaCl 2 , 1.2 mM NaH 2 PO 4 , 1.2 mM MgCl 2 , 11.1 mM glucose, and 21.4 mM NaHCO 3 ) that was saturated with 95% O 2 and 5% CO 2 before recording.
Slices were transferred to a recording chamber and allowed to equilibrate for at least 10 min before recording. The slices were superfused at 34 °C in oxygenated aCSF at a flow rate of 1.8-2.0 ml/min. GFP-or TOMATO-labeled neurons in the ARH were visualized using epifluorescence and infrared-differential sandwich ELISA, the same procedure was used, except for the use of a goat anti-His polyclonal antibody (Abcam) as the detection antibody. EDTA plasma (10 µl of 0.5 M EDTA per 100 µl blood, plasma separated from red blood cells by centrifugation at 1,500g for 15 min at 4 °C) was used for plasma sandwich ELISAs. For the western blot analysis of mammalian asprosin, 40 µg mammalian asprosin was enzymatically deglycosylated using a protein deglycosylation mix (New England Biolabs). 20 µg glycosylated mammalian asprosin, 40 µg deglycosylated mammalian asprosin, and 20 µg bacterial rAsprosin were analyzed for molecular weight comparison.
Characterization of the monoclonal antibody against mouse asprosin An in vitro assay to test the potential of a mouse IgG mAb to neutralize asprosin was performed. To evaluate the mAb's neutralization potential, 10 nM rAsprosin was incubated with varying molar ratios of the mAb for 1 h on ice, and unbound asprosin was measured using our sandwich ELISA. The in vitro IC 50 value was calculated using GraphPad Prism 6 software, based on either the residual concentration or the absolute extinction values. Using guidelines from the UK's National Centre for the Replacement, Refinement, and Reduction of Animals in Research (NC3Rs) (https://www.nc3rs.org.uk/mouse-decision-tree-blood-sampling; retrieved on 2/1/2017) to estimate the blood volume of a 50-g mouse, and setting the mAb molecular weight at 150 kDa, we determined that 44 µg mAb per 50-g mouse was sufficient to neutralize 50% of endogenous asprosin.
Epitope mapping of mouse anti-asprosin. Eleven octamer peptides with a two-amino-acid overlap covering the known immunization peptide used for developing the mouse asprosin-specific mAb (KKKELNQLEDKYDKDYLSGE LGDNLKMK) were printed in spots on glass slides by Raybiotech (Raybiotech, Norcross, GA) and incubated with the monoclonal antibody. The antibody was detected using a biotinylated anti-mouse antibody, followed by streptavidin conjugated with a fluorophore. Fluorescence of spots that corresponded to specific octamer peptides was recorded. The results were reported in raw fluorescence (arbitrary numbers), where the highest number signified the strongest fluorescence value and strongest antibody binding.
Plasma asprosin half-life and peak concentration. Mammalian-expressed asprosin (University of North Carolina at Chapel Hill) was labeled with biotin using a EZ-Link Sulfo-NHS-Biotin kit (Thermo Scientific), and excess biotin was removed using a Zeba Spin desalting column (Thermo Scientific). Final protein concentration was estimated using a BCA assay (Thermo Scientific). Approximately 60 µg/mouse of labeled asprosin was injected subcutaneously into WT mice. Blood was drawn before injection (baseline), and at 30, 60, 120, and 360 min after injection, as well as at 24 h and 48 h after injection. The plasma concentration of biotinylated asprosin was determined using a custom designed sandwich ELISA. A plate was coated with the anti-asprosin mAb (capture antibody), total plasma asprosin was bound, and only biotinylated asprosin was selectively detected using HRP-conjugated streptavidin. Halflife was calculated using GraphPad Prism 6 software. A 60-µg subcutaneous dose of mammalian asprosin was found to result in a 40 nM peak plasma level 30 min after injection.
Human and mouse adiponectin, leptin, ghrelin, thyroid stimulating hormone (TSH) , free triiodothyronine (T3), and free thyroxine (T4). Human adiponectin, mouse adiponectin, human leptin, mouse leptin, human ghrelin (total) and mouse ghrelin (total) ELISA kits (Millipore, Billerica, MA) were used to determine the concentrations of each hormone in flash-frozen, previously unthawed plasma as per the manufacturer's instructions. TSH, free T3, and free T4 were measured using an ELISA kit (Monobind Inc., CA) as per the instructions provided.
Statistical analysis.
All results are presented as mean ± s.e.m. P values were calculated by unpaired, two-tailed Student's t-test, or by one-way or two-way ANOVA, followed by appropriate post hoc tests. The type of test used is indicated in the figure legend. For Fbn1 NPS/+ mice, data were additionally analyzed using analysis of covariance (ANCOVA) to account for covariates. For Supplementary  Figure 2b , a χ 2 test was used. Box plots show whiskers at the minimum and maximum, the box around the 25th-75th percentile, line at median, dot at mean where appropriate. No data were excluded, except for outliers as determined by the Grubbs' outlier test (α = 0.05). Animals were excluded if they were found to be sick or died prematurely (less than 5% of animals). In experiments involving different genotypes, investigators were not blinded. For experiments involving the same genotype, but treatment with rAsprosin, rGFP, anti-asprosin, or IgG, animals were randomly assigned into groups with equal mean and standard error, and data were obtained in a blinded fashion. Food intake, energy expenditure, and body composition measures were performed in a blinded fashion, as long as the genotype was not visually obvious (extreme leanness or difference in fur color). Neuronal experiments were performed in an unblinded manner. For mice, a minimum of five mice were used per group. Based on prior experience, we assumed a coefficient of variation of 30%, and with a minimum of five mice we were able to detect a 1.5-fold difference in the means with >80% power and a 1.75-fold difference in the means with 99% power. For the two rat CSF experiments, with an expected difference of >2-fold, a minimum of four rats were used per group. We assumed a coefficient of variation of 30% and were able to detect a 1.5-fold difference in the means with 65% power and a 1.75-fold difference in the means with 95% power. For electrophysiology experiments, a minimum of eight neurons were used per group. For an assumed coefficient of variation of 30%, we were able to detect a 1.25-fold difference in the means with 52% power, a 1.5-fold difference with 92% power, and a 1.75-fold difference with 100% power. n values for each experiment state the number of animals per group, or biological samples from that number of animals, except for electrophysiology experiments, for which the n values describe the number of total neurons analyzed per treatment. Symbols in figures correspond to the following significance levels: *P < 0.05, **P < 0.01, and ***P < 0.001. 
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n/a Confirmed The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
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Fbn1<NPS/+> mice are available on reasonable request.
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Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species).
The anti-asprosin monoclonal antibody was validated using ELISA and loss-offunction experiments in vivo and in vitro. In addition the epitope was verified with binding studies, and dilution series and response curves were analyzed. n/a
